"There's no best, but we'll do better. Your satisfaction is our greatest motivation."

Yibeidatrading

CJC1295(Without DAC)5mg+IPA5mg

(0)View
4152 Sold
CJC-Ipamorelin Blend combines CJC-1295 (No DAC) and Ipamorelin for dual-receptor signaling pathway research. 99%+ purity. For laboratory research only. Research Use Only.
${{shopModel.rebate>0?shopModel.discountPriceStr:shopModel.formattedAmount}} $ {{shopModel.formattedAmount}}
{{item.name}} {{item.imgVal}}
COUPON
COUPON
No minimum spend Order total exceeds ${{item.fullAmount}} ${{item.money}} {{item.rebate}}% OFF ${{item.money}} {{item.rebate}}% OFF
Copy code
Quantity:
Estimated Delivery Date: May 21 - May 21
Frequently Asked Questions
How can I contact customer service?
Do you ship overseas?
How long will it take to get my order?
Specifications

CJC-Ipamorelin Blend – Premium Research Peptide

CJC-Ipamorelin Blend is a combination of two complementary peptides: CJC-1295 (No DAC), a GHRH analog, and Ipamorelin, a selective GHS-R agonist. This blend has become a widely used research tool due to the synergistic mechanisms of its components in activating complementary receptor pathways.

This product is intended for laboratory and research purposes only. Research Use Only.

Component Overview

CJC-1295 (No DAC), also known as Modified GRF (1-29), is a 29-amino acid GHRH analog that binds to GHRH receptors, activating downstream signaling cascades involved in endocrine pathway regulation.

Ipamorelin is a pentapeptide that acts as a selective agonist at GHS-R (ghrelin receptor), engaging a complementary receptor pathway. Research suggests Ipamorelin demonstrates selectivity for the GHS-R without significant cross-reactivity at other endocrine receptor targets.

Research Applications

The CJC-Ipamorelin combination provides researchers with a tool for investigating dual-receptor signaling dynamics:

  • GHRH receptor and GHS-R co-activation mechanisms
  • Dual-pathway signaling cascade interactions
  • Synergistic effects on receptor-mediated pulsatile signaling
  • Downstream pathway modulation research
  • Endocrine axis signaling studies
  • Comparative studies with single-peptide protocols
  • Multi-receptor agonist combination dynamics

Research suggests that combining GHRH analogs with GHS-R agonists may produce additive or synergistic effects on downstream signaling compared to either compound alone.

Technical Specifications

  • Components: CJC-1295 (No DAC) + Ipamorelin
  • CJC-1295 CAS: 863288-34-0
  • Ipamorelin CAS: 170851-70-4
  • Purity: ?99%
  • Form: Lyophilized powder
  • Storage: Store at -20°C, protected from light

Why Choose Bayside Peptides?

  • 99%+ Purity – Premium quality research peptides
  • 2-Day Shipping – Fast and secure delivery
  • Expert Support – Questions? Call us at (800)-750-8812

Disclaimer: This product is sold for research, laboratory, and analytical purposes only. Intended exclusively for qualified professionals in controlled research environments. Research Use Only.

CUSTOMER REVIEWS

{{commentStat.averageRating}}

{{commentStat.total}} Revirews

{{(commentStat.praiseData.length - index)}} Star
{{item.scale}}
All({{commentStat.total}}) Images({{commentStat.imgSum}}) 5 Star({{commentStat.praiseSum}})
Write a Review
Only customers who purchased this item are allowed to leave a review.
Inquire for more cooperation or product information.
We will contact you within 1 business day. Please check your email.
Name
Mail
Phone
Message
Send

My website store

We reply immediately
Welcome to our website. Ask us anything 🎉

Start Chat with:

Subscribe today to hear first about our sales